Additionally, antibody-drug conjugates (ADC) targeting VEGF-VEGFR pathways represent another promising modality, combining precise targeting of angiogenic signaling with the delivery of cytotoxic agents to inhibit tumor growth and angiogenesis.694 Concurrently, artificial intelligence (AI) is revolutionizing drug discovery by identifying dual-target VEGFR inhibitors with greater precision.424 Coupled with genomic and transcriptomic profiling, AI provides critical insights into oncogenic pathways, enabling biomarker development and rational combination therapies. The gene discussed is KDR; the disease is neoplasm.